Newsletter sign up

ADC University Our services

ADC Review
is made possible by:

Copyright 2018
Terms & Conditions

LegoChem Biosciences Receives US Patent for Proprietary ConjuAll ADC Platform Technology

Published on 17th April

South Korean LegoChem Biosciences, earlier today confirmed that the Company was awarded a new U.S. Patent for ConjuAll™ technology, the company’s proprietary ADC platform which enables the design of homogeneous plasma stable antibody-drug conjugates or ADCs with the potential for improved payload delivery to cancer cells. This patent provides LegoChem with comprehensive patent protection in the United States for its ADC platform technology.

ConjuAll™ is a next-generation ADC platform technology utilizing novel linker chemistry combined with site-specific enzymatic conjugation. The platform technology offers a number of solutions for site-specific conjugation, linker stability and efficient payload release which remain major unmet needs in the development of novel ADC.

“This patent further strengthens LCB’s competitive advantage in the field of research and development of next generation ADCs. The use of our technology will address significant unmet needs of current ADC technologies,” noted Yeong Soo Oh, Ph.D, Senior Vice President & Chief Technology Officer of LegoChem.

Development success

Estab;ished in 2006, the company, which focuses on the research & development of antibody-drug conjugates, has been successfully developing a number of global partnerships through the potential of its proprietary ADC platform technology.

In 2015, LegoChem out-licensed an anti-Her2-ADC molecule (LCB14-0110) to Fosun Pharma and earlier this year, in January 2017, the company signed a research licensing deal with Takeda, to evaluate next-generation ADC candidates.

In February the company signed an agreement with Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, to evaluate an antibody drug conjugate candidate. As part of the research collaboration, Novimmune brings expertise in the field of targeted therapies with their anti-CD47/anti-CD19 and anti-CD47/anti-mesothelin bispecific antibodies that selectively bind to hematological and solid tumors, respectively.


Last Editorial Review: April 17, 2017

Featured Image: Scientist using microscope in the laboratoryCourtesy: © 2017 Fotolia. Used with permission.

Copyright © 2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Print Friendly, PDF & Email

Leave a Reply

Skip to toolbar